Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B4T2-001 CAR-T in advanced solid tumors
NCT06072989Phase 1Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B4t2-001 in solid tumor (advanced stage), sponsored by Shanghai East Hospital. Primary endpoints: Incidence and severity of adverse events (AEs) at 2 years, Maximum Tolerated Dose at 2 years and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
B4t2-001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06072989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072989.